ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Teva Pharmaceutical Industries is selling four diverse early-clinical and preclinical oncology programs to San Diego-based Ignyta, which will give Teva 6% of Ignyta’s common stock. At the same time, Teva will pay $15 million for another 6% of Ignyta’s stock. Ignyta gains CEP-32496, which blocks the genes BRAF, EGFR, and RET and is in a Phase I/II study, and three preclinical assets: CEP-40783, a pseudo-irreversible inhibitor of AXL and cMet; CEP-40125, a nanoformulation of a modified bendamustine; and TEV-44229, which blocks the atypical kinase PKCiota.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter